πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Theravance Biopharma Ireland Patents

Full USPTO pharma patent portfolio for Theravance Biopharma Ireland β€” grant dates, expiration, and drug cross-links.

Patents
635
Expiring ≀24m
58

Quick answer

Theravance Biopharma Ireland has 635 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 58 expire within 24 months β€” use filters for patent-cliff planning.

Page 2 of 14

  1. US 11254655

    Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11254669

    Fused imidazo-piperidine JAK inhibitors

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11247969

    Biphenyl compounds useful as muscarinic receptor antagonists

    Expires Mon Feb 10 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11230536

    Crystalline (2S,4R)-5-(5β€²-chloro-2β€²-fluoro-[1,1β€²-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11174219

    Neprilysin inhibitors

    Expires Mon Nov 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11160800

    Methods of treatment using a JAK inhibitor compound

    Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11160810

    Fused imidazo-piperidine JAK inhibitor compound

    Expires Mon Oct 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11155549

    Ester and carbonate pyrimidine compounds as JAK kinase inhibitors

    Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11124502

    Neprilysin inhibitors

    Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11110095

    Pyrimidine compounds as JAK kinase inhibitors

    Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11033533

    (2R,4R)-5-(5β€²-chloro-2β€²-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

    Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11008289

    Crystalline freebase forms of a biphenyl compound

    Expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10988470

    Pyrimidine compound as JAK kinase inhibitor

    Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10968205

    Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors

    Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10968222

    2-azabicyclo hexane JAK inhibitor compound

    Expires Mon Apr 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10961267

    Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease

    Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10954237

    JAK inhibitors containing a 4-membered heterocyclic amide

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10952996

    ALK5 inhibitors

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10947254

    Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10946006

    Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10946007

    4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10946009

    Combination dosage form of a mu opioid receptor antagonist and an opioid agent

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10913740

    JAK kinase inhibitor compounds for treatment of respiratory disease

    Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10851102

    Imidazole and triazole containing bicyclic compounds as JAK inhibitors

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10836744

    Diamide compounds having muscarinic receptor antagonist and Ξ²2 adrenergic receptor agonist activity

    Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10836763

    5 to 7 membered heterocyclic amides as JAK inhibitors

    Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10829438

    Neprilysin inhibitors

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10774080

    Pyrimidine compound as JAK kinase inhibitor

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10759813

    Neprilysin inhibitors

    Expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10752599

    Crystalline (2S,4R)-5-(5β€²-chloro-2β€²-fluoro-[1,1β€²-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof

    Expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10744104

    Neprilysin inhibitors

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10745405

    Glucuronide prodrugs of Janus kinase inhibitors

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10745394

    8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

    Expires Mon Aug 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10722504

    4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds

    Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10696656

    Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists

    Expires Mon Jun 25 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10590107

    Diamide compounds having muscarinic receptor antagonist and Beta2 adrenergic receptor agonist activity

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10577347

    Crystalline forms of a biphenyl compound

    Expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10576073

    Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound

    Expires Mon Feb 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10570120

    Neprilysin inhibitors

    Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10570092

    Biphenyl compounds useful as muscarinic receptor antagonists

    Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10562894

    Pyrimidine compound as JAK kinase inhibitor

    Expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10550081

    Crystalline freebase forms of a biphenyl compound

    Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10548879

    (2R,4R)-5-(5β€²-chloro-2β€²-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

    Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10550118

    JAK inhibitors containing a 4-membered heterocyclic amide

    Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10548886

    Methods of treatment using a JAK inhibitor compound

    Expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10538513

    Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors

    Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10526330

    JAK kinase inhibitor compounds for treatment of respiratory disease

    Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10519153

    Fused imidazo-piperidine JAK inhibitors

    Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Theravance Biopharma Ireland have?

635 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Theravance Biopharma Ireland patents expire?

58 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.